REGEN BIOPHARMA, INC. (RGBPP) Operating margin 2017–2025
REGEN BIOPHARMA, INC. (RGBPP) operating margin by fiscal year — reported operating income divided by reported revenue.
-143.1%FY2025 · since FY2017: -2282.6% → -143.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -143.1% | +33.3 pp |
| FY2024 | -176.4% | +114.0 pp |
| FY2023 | -290.4% | -19.8 pp |
| FY2022 | -270.6% | +57.5 pp |
| FY2021 | -328.1% | -137.8 pp |
| FY2020 | -190.3% | +497.7 pp |
| FY2019 | -688.0% | +737.8 pp |
| FY2018 | -1425.8% | +856.8 pp |
| FY2017 | -2282.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBPP financial trends
RGBPP RevenueRGBPP Net incomeRGBPP Net marginRGBPP Gross profitRGBPP Gross marginRGBPP Operating incomeRGBPP Operating cash flowRGBPP Free cash flowRGBPP Capital expendituresRGBPP Return on equityRGBPP Stock buybacksRGBPP Dividends paidRGBPP Total assetsRGBPP Total liabilitiesRGBPP Shareholders’ equityRGBPP overview →